Inovio Pharmaceuticals (NSDQ:INO) and its partner, GeneOne Life Science (KSE:011000), said today that the companies have dosed the first patient in a Phase I study designed to test a preventive vaccine against hepatitis C infection.
The companies plan to recruit 24 study participants to evaluate Inovio’s GLS-6150 candidate. Participants will include people who have a sustained virologic response following treatment for Hep. C, as well as healthy controls. They are slated to receive one of two doses of vaccine, administered intra-dermally and followed by electroporation with Inovio’s Cellectra device.
Get the full story at our sister site, Drug Delivery Business News.
The post Inovio launches Ph1 study of Hep C vaccine appeared first on MassDevice.
from MassDevice https://ift.tt/2wF3qPJ
Cap comentari:
Publica un comentari a l'entrada